SCHEMBL5565237

SCHEMBL5565237

COc1cc2ncnc(Nc3cccc(NC(=O)CC#N)c3)c2cc1OC

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
EGFR P00533 6/20 0.67
MAPK14 Q16539 2/20 0.67
SRC P12931 2/20 0.67
ABCG2 Q9UNQ0 1/20 0.64
PDGFRB P09619 2/20 0.64
FLT4 P35916 2/20 0.64
KDR P35968 7/20 0.63
RET P07949 4/20 0.62
FGFR1 P11362 1/20 0.62
FLT1 P17948 1/20 0.62
CDK2 P24941 1/20 0.62
PIK3R1 P27986 1/20 0.62
EPHB2 P29323 1/20 0.62
KIF5B P33176 1/20 0.62
TTBK1 Q5TCY1 1/20 0.62
LRRK2 Q5S007 3/20 0.61
NOD1 Q9Y239 1/20 0.61
KIT P10721 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5569223 0.91 KDR (0.77) EGFRKDRRET
SCHEMBL6786328 0.84 EGFR (0.77) EGFRMAPK14SRCABCG2KDR
Hydrochloric Acid SCHEMBL6793841 0.81 MAPK14 (0.77) EGFRMAPK14SRCABCG2KDR
SCHEMBL6785711 0.81 MAPK14 (1.00) EGFRMAPK14SRCKDR
SCHEMBL7507820 0.81 SRC (1.00) EGFRMAPK14SRCKDRRET
SCHEMBL5485308 0.80 EGFR (0.77) EGFRMAPK14SRCABCG2KDR
Hydrochloric Acid SCHEMBL6794010 0.79 MAPK14 (0.81) EGFRMAPK14SRCABCG2PDGFRB
Hydrochloric Acid SCHEMBL5471735 0.79 EGFR (0.75) EGFRMAPK14SRCABCG2KDR
SCHEMBL13978492 0.79 EGFR (1.00) EGFRSRCABCG2
SCHEMBL6668330 0.79 EGFR (0.70) EGFRMAPK14SRCABCG2KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections GPC BIOTECH AG (DE) 2007-05-31 US claimed
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections GPC BIOTECH AG (DE) 2007-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections IRF3, PML, TPMT EGFR 1445/4885MAPK14 423/4885SRC 1085/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.